Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

Published on by Forensic Scientist

Dr. Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

University of Wisconsin-Madison | United States

Dr. Jacques Galipeau is a leading translational immunologist recognized for seminal contributions to mesenchymal stromal cell (MSC) biology, immune modulation, and engineered cytokine therapeutics. His research has reshaped global understanding of MSC immunogenicity, functional potency, and clinical limitations, directly influencing regulatory science and advanced cell therapy development. He pioneered the discovery and translation of fusokines, a novel class of synthetic cytokines with applications in autoimmunity, cancer immunotherapy, transplantation tolerance, and regenerative medicine. His work bridges mechanistic immunology and first-in-human translation, with sustained impact across academia and clinical development. According to Google Scholar, Dr. Jacques Galipeau has authored 478 peer-reviewed publications, received 23244 citations, and holds an h-index exceeding 71, reflecting sustained global influence.

                        Citation Metrics (Google Scholar)

30000

25000

20000

15000

10000

5000

0

 

Citations
23444
Documents
478
h-index
71

Citations

Documents

h-index

View Google Scholar Profile

Featured Publications


Mesenchymal stromal cells: clinical challenges and therapeutic opportunities

– J. Galipeau, L. Sensébé · Cell Stem Cell, 2018 · Cited by 1868


Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages

– J.S. Wang, D. Shum-Tim, J. Galipeau et al. · J Thorac Cardiovasc Surg, 2000 · Cited by 976


Mesenchymal stem versus stromal cells: ISCT® position statement on nomenclature

– S. Viswanathan, Y. Shi, J. Galipeau et al. · Cytotherapy, 2019 · Cited by 866

Human MSC suppression correlates with cytokine-induced IDO and M2 macrophage differentiation

– M. François, R. Romieu-Mourez, M. Li, J. Galipeau · Molecular Therapy, 2012 · Cited by 862

Allogeneic marrow stromal cells are immune-rejected by MHC-mismatched recipients

– N. Eliopoulos, J. Stagg, L. Lejeune et al. · Blood, 2005 · Cited by 700

Ying Cui | Immunology and Microbiology | Excellence in Research Award

Published on by Forensic Scientist

Ms. Ying Cui | Immunology and Microbiology | Excellence in Research Award

Beijing Friendship Hospital, Capital Medical University | China

Ms. Ying Cui is an emerging neuroscientist whose research advances the understanding of the gut–brain axis, neurodegeneration mechanisms, and biomarker innovation in Parkinson’s disease (PD). Her work integrates metagenomics, multi-parameter clinical imaging, molecular neuroscience, and machine-learning analytics to improve diagnostic precision and support translational therapeutic development. With 6 Scopus-indexed publications, 85 citations, and an h-index of 2, her research impact continues to grow across both clinical and experimental domains. Ms. Ying Cui has contributed to high-value research projects, including multicenter clinical trials and national-level neuroscience studies, where she played key roles in microbiome profiling, experimental methodology, and advanced neuroimaging assessment using ¹²³I-MIBG scintigraphy. Her first-author publications provide novel insights into the diagnostic performance of cardiac and extra-cardiac washout rate parameters for differentiating PD from Parkinson-plus syndromes, offering clinically relevant imaging markers for complex diagnostic scenarios. Complementing her imaging research, Ying has developed a high-accuracy metagenomic diagnostic model with 99% validation accuracy and identified functional probiotic strains with the potential to modulate α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammatory signaling work that has led to a PCT international patent for a probiotic composition targeting REM Sleep Behavior Disorder. Her multidisciplinary contributions span biomarker discovery, clinical–computational integration, translational microbiome innovation, and cross-institutional collaborations in neurology, microbiology, metabolomics, and bioinformatics. Through this synergistic research portfolio, Ying Cui continues to advance early diagnostic strategies, mechanistic insights, and therapeutic innovation in Parkinson’s disease, establishing herself as a rising researcher in translational neurodegeneration science.

Profiles: Scopus | ORCID

Featured Publications

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of extra-cardiac sympathetic nervous uptake parameters based on ¹²³I-MIBG SPECT/CT in the assessment of Parkinson’s disease. Clinical and Translational Imaging.

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson’s disease. EJNMMI Research.

Fizza Khalid | microbiology | Best Researchrer Award

Published on by Forensic Scientist

Dr. Fizza Khalid | microbiology | Best Researcher Award

clinical scientist at Dr Sulaiman Al-Habib Medical Diagnostic Laboratory , Saudi Arabia

Dr. Fizza Khalid is a dedicated microbiologist with extensive expertise in laboratory research, antimicrobial resistance, and clinical microbiology. With a Ph.D. in Medical Microbiology from the University of Health Sciences, Lahore, she has a proven track record of characterizing drug-resistant bacteria and developing innovative treatment strategies. Currently, she is the Deputy Head of the Clinical Research Committee and a Specialized Lab Supervisor at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. Dr. Khalid is passionate about advancing microbiological research to improve healthcare outcomes and has published several impactful studies in leading international journals.

Profile

ORCID

Educational

  • Ph.D. in Medical Microbiology (2016–2023) – University of Health Sciences, Lahore
    Thesis: Characterization of Locally Isolated Acinetobacter baumannii Strains for Drug Resistance and Biofilm Formation
  • M.Phil. in Medical Microbiology (2012–2014) – University of Health Sciences, Lahore
    Thesis: In-vitro Efficacy of Polymyxin B with Rifampin, Colistin, and Doxycycline Against Extensively Drug Resistant Acinetobacter baumannii
  • M.Sc. in Medical Technology (2008–2010) – University of Health Sciences, Lahore
    Thesis: Frequency of Extended Spectrum Beta Lactamase Enzymes in the Clinical Isolates of Salmonella Typhi
  • B.Sc. in Medical Laboratory Technology (2005–2007) – University of Health Sciences, Lahore

Professional Experience

Dr. Fizza Khalid currently serves as the Deputy Head of the Clinical Research Committee and Specialized Lab Supervisor in Microbiology at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. In her role, she leads clinical microbiology operations, collaborates with healthcare professionals, ensures regulatory compliance, and conducts research presented at international conferences. Previously, she was a Senior Lab Technologist at the same group, where she developed standard operating protocols, performed clinical microbiology analysis, and ensured testing quality and safety compliance. Throughout her career, Dr. Khalid has mentored junior researchers, promoted clinical research, and conducted workshops to enhance scientific study design and writing skills.

Research Interests

Dr. Khalid’s research focuses on antimicrobial resistance, particularly in Acinetobacter baum                                                                                             annii and Salmonella Typhi, biofilm formation, and the effectiveness of novel treatment strategies against drug-resistant bacterial strains. She has a keen interest in developing antimicrobial agents, studying bacterial genotyping, and investigating synergistic antibiotic combinations to combat multidrug-resistant pathogens. Her research contributes to understanding the molecular mechanisms of resistance and finding practical applications for improving patient care in clinical settings.

Author Metrics

  • Published Papers: 14 peer-reviewed articles, including journals such as Clinica Chimica Acta, JPMA, Scientific Reports, and Annals of Clinical Microbiology and Antimicrobials.
  • Citations: Her work has been widely cited in the fields of antimicrobial resistance and biofilm research.
  • H-index: Reflects her contributions to microbiology, particularly in research related to Acinetobacter baumannii and Salmonella Typhi.

Publication

Conclusion

Fizza Khalid presents an excellent case for the Best Researcher Award in medical microbiology, with notable strengths in antibiotic resistance research, an impressive publication record, and practical lab expertise. Her leadership role in facilitating junior researchers and fostering a culture of research also speaks to her broader contribution to the scientific community. With a few targeted improvements, such as securing international collaborations and focusing her research scope, she can further strengthen her candidacy for the award.

In conclusion, Khalid’s achievements in medical microbiology, particularly her work on MDR pathogens, make her a strong contender for the Best Researcher Award, demonstrating both scientific excellence and leadership in her field.